PR
PTCT icon

PSP Research’s PTC Therapeutics PTCT Stock Holding History

PSP Research’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$489K Hold
6,000
– – 0.26% 21
2026
Q1 		$409K Sell
6,000
-1,046
-15% -$74.1K 0.29% 46
2025
Q4 		$535K Buy
+7,046
New +$512K 0.47% 28

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

PSP Research's PTCT Position: Q2 2026 in Review

PSP Research held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 6,000 shares worth $489K. The position accounts for 0.26% of the portfolio, ranked #21.

PSP Research first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $535K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • PSP Research held 6,000 shares of PTC Therapeutics worth $489K as of Q2 2026.
  • PSP Research left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up 0.26% of PSP Research's portfolio in Q2 2026, its #21 holding.
  • PSP Research first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's PTC Therapeutics position peaked at $535K in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.